Onvatilimab, referred to as JNJ-61610588, represents a innovative medicinal antibody directed towards {PD-1 | the PD-1 protein) and currently undergoing clinical trials for various {cancer | malignant https://onvatilimab141427.blog-gold.com/59710445/onvatilimab-a-in-depth-investigation-into-the-jnj-61610588-protein